Targeting Infectious Disease - for a Safer World
The Company is developing small molecule drug candidates for the treatment of Anthrax intoxication following exposure to Anthrax spores and for treatment of botulism in humans caused by BoNT type A intoxication.
Hawaii Biotech’s recombinant subunit protein vaccine pipeline includes a number of candidates targeting emerging and re-emerging infectious diseases. Our stable insect cell vaccine platform supports all of our vaccine candidates.
Hawaii Biotech’s protein production platform results in the expression of high quality proteins that maintain native-like structure. Proteins produced by HBI have been shown to elicit immune responses equivalent to, or better than traditional live-attenuated or inactivated virus approaches. Our semi-synthetic saponin adjuvant, GPI-0100, helps elicit broad immune responses to both vaccines and therapeutics.
The Company is developing small molecule drug candidates for the treatment of Anthrax intoxication following exposure to Anthrax spores and for treatment of botulism in humans caused by BoNT type A intoxication.
Hawaii Biotech’s recombinant subunit protein vaccine pipeline includes a number of candidates targeting emerging and re-emerging infectious diseases. Our stable insect cell vaccine platform supports all of our vaccine candidates.
Hawaii Biotech’s protein production platform results in the expression of high quality proteins that maintain native-like structure. Proteins produced by HBI have been shown to elicit immune responses equivalent to, or better than traditional live-attenuated or inactivated virus approaches. Our semi-synthetic saponin adjuvant, GPI-0100, helps elicit broad immune responses to both vaccines and therapeutics.